| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/17/2000 | WO1999065942A8 Cyclic somatostatin analogs |
| 02/17/2000 | WO1999063931A3 Peptidyl-prolyl cis-trans isomerase inhibitors and uses therefor |
| 02/17/2000 | WO1999063101A3 Transfected cells and methods for treating diabetes |
| 02/17/2000 | WO1999062534B1 IL-6/sIL-6R COMPLEX FOR PROMOTION OF LIVER FUNCTIONS |
| 02/17/2000 | WO1999061613A3 Interference with viral ires-mediated translation by a small yeast rna reveals critical rna-protein interactions |
| 02/17/2000 | WO1999061039A3 Novel composition for modulating ischemic cell death |
| 02/17/2000 | WO1999058691A3 Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| 02/17/2000 | WO1999058126B1 Use of neomycin for treating angiogenesis-related diseases |
| 02/17/2000 | WO1999057289A3 INHIBIN-HBc FUSION PROTEIN |
| 02/17/2000 | WO1999057241A9 Myelin basic protein peptides and uses thereof |
| 02/17/2000 | WO1999056784A3 Inprovements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor or interleukin-10 |
| 02/17/2000 | WO1999056763A9 Use of neglected target tissue antigens in modulation of immune responses |
| 02/17/2000 | WO1999055859A3 Cd40-interacting and traf-interacting proteins |
| 02/17/2000 | WO1999053036A9 Ste20-related protein kinases |
| 02/17/2000 | WO1999051779A9 Glaucoma therapeutics and diagnostics |
| 02/17/2000 | WO1999050461A9 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 02/17/2000 | WO1999050386A3 Human telomerase catayltic subunit variants |
| 02/17/2000 | WO1999049909A9 Revascularization apparatus having coaxial channeling and injecting means |
| 02/17/2000 | WO1999049803A9 Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation |
| 02/17/2000 | WO1999046371A9 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| 02/17/2000 | WO1999045955A9 DIAGNOSIS, PREVENTION AND TREATMENT OF ULCERATIVE COLITIS, AND CLINICAL SUBTYPES THEREOF, USING MICROBIAL UC pANCA ANTIGENS |
| 02/17/2000 | CA2728907A1 Peg-urate oxidase conjugates and use thereof |
| 02/17/2000 | CA2339638A1 Monocyclic compounds having nk-2 antagonist action and compositions containing them |
| 02/17/2000 | CA2339485A1 Protease inhibitors for use in the treatment of psoriasis |
| 02/17/2000 | CA2339416A1 Short oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | CA2339413A1 Method for treatment of invasive cells |
| 02/17/2000 | CA2339378A1 Preparations containing hepatocyte growth factor for treating ischemic diseases by intramuscular administration |
| 02/17/2000 | CA2339352A1 N-acetylglycosaminyltransferase genes |
| 02/17/2000 | CA2339348A1 Oligomers which inhibit expression of collagen genes |
| 02/17/2000 | CA2339347A1 Novel g protein-coupled receptor cdna sequence |
| 02/17/2000 | CA2339340A1 Antisense oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | CA2339322A1 Genes involved in the molecular paths for tumour suppression and /or resistance to viruses |
| 02/17/2000 | CA2339086A1 Dna replication- and repair-associated proteins |
| 02/17/2000 | CA2339085A1 Conjugates targeted to the interleukin-2 receptors |
| 02/17/2000 | CA2339018A1 Fsh mimetics for the treatment of infertility |
| 02/17/2000 | CA2338385A1 Human receptor-associated proteins |
| 02/17/2000 | CA2337964A1 Treatment of central nervous system ischemia or trauma with epidermal growth factor-like polypeptides |
| 02/17/2000 | CA2337904A1 Novel genes in control of hematopoiesis |
| 02/17/2000 | CA2337712A1 Molecules designated b7l-1 |
| 02/17/2000 | CA2337083A1 Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof |
| 02/17/2000 | CA2336523A1 Immunological herpes simplex virus antigens and methods for use thereof |
| 02/17/2000 | CA2335648A1 A novel g protein-coupled receptor protein and its dna |
| 02/17/2000 | CA2305198A1 Solution for resuscitating multicellular organism cells and method for resuscitating multicellular organism cells by using the same |
| 02/17/2000 | CA2280449A1 Stabilized protein compositions |
| 02/16/2000 | EP0979871A1 NOVEL dlg FAMILY MOLECULE, POLYNUCLEOTIDE ENCODING THE SAME, ANTIBODY AGAINST THE SAME, AND METHOD FOR DETECTING dlg GENE |
| 02/16/2000 | EP0979870A1 Human Wnt-6 polypeptide |
| 02/16/2000 | EP0979869A1 Short oligonucleotides for the inhibition of VEGF expression |
| 02/16/2000 | EP0979831A2 Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient |
| 02/16/2000 | EP0979827A1 Peptides having tachykinin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same |
| 02/16/2000 | EP0979648A2 Microspheres of esters of hyaluronic acid for controlled release of an active |
| 02/16/2000 | EP0979614A2 Method of producing iron-whey-proteolysate complex |
| 02/16/2000 | EP0979292A2 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety |
| 02/16/2000 | EP0979290A2 Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors |
| 02/16/2000 | EP0979289A1 Human lysophospholipase |
| 02/16/2000 | EP0979284A2 Methods and reagents for vaccination which generate a cd8 t cell immune response |
| 02/16/2000 | EP0979282A1 Rat st38.2 chemokine |
| 02/16/2000 | EP0979281A2 A method for making multispecific antibodies having heteromultimeric and common components |
| 02/16/2000 | EP0979280A1 Polynucleotides encoding a cd53-like transmembrane protein |
| 02/16/2000 | EP0979279A2 Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging |
| 02/16/2000 | EP0979276A1 Complement receptor type 1 (cr1)-like sequences |
| 02/16/2000 | EP0979275A1 Novel human mago nashi protein |
| 02/16/2000 | EP0979274A2 Human p24 vesicle proteins |
| 02/16/2000 | EP0979273A1 MODIFIED ANTISENSE NUCLEOTIDES COMPLEMENTARY TO A SECTION OF THE HUMAN Ha-Ras GENE |
| 02/16/2000 | EP0979272A1 Strl33, a human fusion accessory factor associated with hiv infection |
| 02/16/2000 | EP0979246A2 Man monoclonal antibodies to epidermal growth factor receptor |
| 02/16/2000 | EP0979245A1 Oligopeptidic inhibitors of elastases and methods of preparation thereof |
| 02/16/2000 | EP0979244A1 Novel cyclosporin derivatives, preparation and pharmaceutical compositions containing same |
| 02/16/2000 | EP0979243A2 Activation of peptides |
| 02/16/2000 | EP0979242A2 Substituted oxadiazole cysteine protease inhibitors |
| 02/16/2000 | EP0979241A1 (3r)-3-amino-4-carboxybutyraldehyde derivatives inhibiting the release of interleukin-1/beta |
| 02/16/2000 | EP0979240A1 Serine protease inhibitors |
| 02/16/2000 | EP0979239A1 Prevention and treatment of hepatocellular cancer |
| 02/16/2000 | EP0979238A1 Method of alleviating neuropathic pain |
| 02/16/2000 | EP0979234A1 Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| 02/16/2000 | EP0979225A1 Compounds and compositions for delivering active agents |
| 02/16/2000 | EP0979101A1 Recombinant canine adenovirus (cav) containing exogenous dna |
| 02/16/2000 | EP0979099A1 Use of lactoferin in the treatment of allergen induced disorders |
| 02/16/2000 | EP0979098A1 Method of treating hyperprolactinemia and prolactinomas |
| 02/16/2000 | EP0979097A1 Hgf for treating acute renal failure |
| 02/16/2000 | EP0979096A1 Treatment of infarcts through inhibition of nf-kappab |
| 02/16/2000 | EP0979095A2 Use of conantokins for producing analgesia or for neuroprotection |
| 02/16/2000 | EP0979094A2 Agent for enhancing the heart force |
| 02/16/2000 | EP0979092A2 Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| 02/16/2000 | EP0979089A1 Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells |
| 02/16/2000 | EP0979086A2 Method and composition for modulating amyloidosis |
| 02/16/2000 | EP0979080A1 A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent |
| 02/16/2000 | EP0979073A1 Nitrosylation to inactivate apoptotic enzymes |
| 02/16/2000 | CN1244921A Treatment and diagnosis of cancer |
| 02/16/2000 | CN1244894A Tissue type plasminogen activator (t-PA) variants: compositions and methods of use |
| 02/16/2000 | CN1244873A Antibodies that bind to the nidogen-binding domain of laminin, their production and use |
| 02/16/2000 | CN1244872A Glucagon-like peptide-2 analogs |
| 02/16/2000 | CN1244871A H. pylori antigens |
| 02/16/2000 | CN1244860A Cyclic imines as pesticides |
| 02/16/2000 | CN1244805A Stable lyophilized pharmaceutical substance from monoclonal or polyclonal antibodies |
| 02/16/2000 | CN1244804A Peptide immunotherapeutic agent |
| 02/16/2000 | CN1244803A Soluble CTLA4 mutant molecules and uses thereof |
| 02/16/2000 | CN1244802A Reductive alkylation of glycopeptide antibiotics |
| 02/16/2000 | CN1244794A Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same |
| 02/16/2000 | CN1244772A Targeted cytotoxic cell |
| 02/16/2000 | CN1244769A Antimicrobial proteins |